12:00 AM
Sep 22, 2008
 |  BC Week In Review  |  Company News  |  Deals

Ariad deal

Ariad will acquire the 20% of Ariad Gene Therapeutics Inc. it does not already own for about 2.3 million shares valued at $6.9 million based on Ariad's close of $3.08 on Sept. 11, the day...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >